<PAGE>

                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549


                                    FORM 10-Q

(MARK ONE)

    X        QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
  -----                  SECURITIES EXCHANGE ACT OF 1934
                  FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2000


            TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                 FOR THE TRANSITION PERIOD FROM ______ TO_______


                           COMMISSION FILE NO. 1-5439


                             DEL LABORATORIES, INC.
                             ----------------------
             (Exact name of registrant as specified in its charter)


            DELAWARE                                             13-1953103
            --------                                             ----------
(State or other jurisdiction of                               (I.R.S. Employer
 incorporation or organization)                              Identification No.)


                    178 EAB PLAZA, UNIONDALE, NEW YORK 11556
                    ----------------------------------------
               (Address of principal executive offices) (Zip Code)


       Registrant's telephone number, including area code: (516) 844-2020

                                   ----------

Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

                    YES  (X)                       NO  ( )

The number of shares of Common Stock, $1 par value, outstanding as of May 8,
2000 was 7,543,726.

<PAGE>

                     DEL LABORATORIES, INC. AND SUBSIDIARIES

                                      Index


Part I.      FINANCIAL INFORMATION                                          PAGE
                                                                            ----
Item 1.      Financial Statements:

             Consolidated Balance Sheets as of
                March 31, 2000 and December 31, 1999                           3

             Consolidated Statements of Earnings for the three
                months ended March 31, 2000 and 1999                           4

             Consolidated Statements of Cash Flows for the
                three months ended March 31, 2000 and 1999                     5

             Notes to Consolidated Financial Statements                        6

Item 2.      Management's Discussion and Analysis of Financial
             Condition and Results of Operations                               9


PART II.  OTHER INFORMATION                                                   12

SIGNATURES                                                                    13


All other schedules and compliance information called for by the instructions to
Form 10-Q have been omitted since the required information is not present or not
present in amounts sufficient to require submission.


                                       -2-
<PAGE>

                     DEL LABORATORIES, INC. AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEETS
                      MARCH 31, 2000 AND DECEMBER 31, 1999
               (In thousands except for share and per share data)

<TABLE>
<CAPTION>
                                                                   March 31         December 31
                                                                     2000              1999
                                                                   ---------         ---------
                                                                  (UNAUDITED)
<S>                                                                <C>               <C>
                             ASSETS
Current assets:
   Cash and cash equivalents                                       $   2,385         $   3,585
   Accounts receivable-less allowance for doubtful accounts
     of $1,300 in 2000 and 1999                                       56,312            45,942
   Income taxes receivable                                             1,963             1,963
   Inventories                                                        62,990            59,155
   Deferred income taxes, net                                          5,272             5,272
   Prepaid expenses and other current assets                           2,522             2,455
                                                                   ---------         ---------
      Total current assets                                           131,444           118,372

Property, plant and equipment, net                                    39,370            37,191

Intangibles arising from acquisitions, net                            16,881            17,101
Other assets                                                           8,978             7,897
                                                                   ---------         ---------
      Total assets                                                 $ 196,673         $ 180,561
                                                                   =========         =========
               LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
   Notes payable to bank                                           $     664         $   3,888
   Accounts payable                                                   29,917            27,175
   Accrued liabilities                                                15,045            12,837
                                                                   ---------         ---------
      Total current liabilities                                       45,626            43,900

Long-term pension liability, less current portion                      9,052             9,052
Deferred income taxes, net                                               986               986
Long-term debt, less current portion                                  89,486            75,750
                                                                   ---------         ---------
      Total liabilities                                              145,150           129,688
                                                                   ---------         ---------
Shareholders' equity:
   Preferred stock $.01 par value, authorized
   1,000,000 shares; no shares issued                                     --                --
   Common stock $1 par value, authorized
   20,000,000 shares; issued 10,000,000 shares                        10,000            10,000
   Additional paid-in capital                                            127               127
   Accumulated other comprehensive loss                               (1,019)           (1,029)
   Retained earnings                                                  75,637            75,136
                                                                   ---------         ---------
                                                                      84,745            84,234
   Less:  Treasury stock at cost, 2,455,420 shares
     in 2000 and 1999                                                (32,120)          (32,120)
   Receivables for stock options exercised                            (1,102)           (1,241)
                                                                   ---------         ---------
      Total shareholders' equity                                      51,523            50,873
                                                                   ---------         ---------
      Total liabilities and shareholders' equity                   $ 196,673         $ 180,561
                                                                   =========         =========
</TABLE>


         The accompanying notes are an integral part of the consolidated
                             financial statements.

                                       -3-
<PAGE>

                     DEL LABORATORIES, INC. AND SUBSIDIARIES
                       CONSOLIDATED STATEMENTS OF EARNINGS
               FOR THE THREE MONTHS ENDED MARCH 31, 2000 AND 1999
               (IN THOUSANDS EXCEPT FOR SHARE AND PER SHARE DATA)
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                         THREE MONTHS ENDED
                                                              MARCH 31
                                                   -------------------------------
                                                      2000                1999
                                                   -----------         -----------
<S>                                                <C>                 <C>
Net sales                                          $    67,382         $    61,756
Cost of goods sold                                      28,951              27,774
Selling and administrative expenses                     35,490              33,895
                                                   -----------         -----------
    Operating income                                     2,941                  87

Other income (expense):
    Gain on sale of facility                                --               1,734
    Interest expense                                    (2,086)             (1,228)
    Interest income                                          8                  17
                                                   -----------         -----------

Earnings before income taxes                               863                 610
Income taxes                                               362                 244
                                                   -----------         -----------
    Net earnings                                   $       501         $       366
                                                   ===========         ===========
Earnings per common share:
    Basic                                          $      0.07         $      0.05
                                                   ===========         ===========
    Diluted                                        $      0.07         $      0.05
                                                   ===========         ===========
Weighted average common shares outstanding:
    Basic                                            7,545,000           7,621,000
                                                   ===========         ===========
    Diluted                                          7,621,000           8,069,000
                                                   ===========         ===========
</TABLE>


         The accompanying notes are an integral part of the consolidated
                             financial statements.

                                       -4-
<PAGE>

                     DEL LABORATORIES, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
               FOR THE THREE MONTHS ENDED MARCH 31, 2000 AND 1999
                                 (In thousands)
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                                             MARCH 31
                                                                     -------------------------
                                                                       2000             1999
                                                                     --------         --------
<S>                                                                  <C>              <C>
Cash flows from operating activities:
Net earnings                                                         $    501         $    366
Adjustments to reconcile net earnings to net cash
  provided by (used in) operating activities:
Depreciation and amortization                                           1,767            1,758
Provision for doubtful accounts                                            45               --
Gain on sale of facility                                                   --           (1,734)
Other non-cash operating items                                            241              166
Changes in operating assets and liabilities:
    Accounts receivable                                               (10,424)            (735)
    Inventories                                                        (3,851)          (5,401)
    Prepaid expenses and other current assets                             (68)              52
    Other assets                                                       (1,081)             361
    Accounts payable                                                    2,749           (1,326)
    Accrued liabilities                                                 2,208            6,012
    Income taxes payable                                                   --             (312)
                                                                     --------         --------

          Net cash used in operating activities                        (7,913)            (793)
                                                                     --------         --------
Cash flows provided by (used in) investing activities:
    Proceeds from sale of facility                                         --            2,538
    Property, plant and equipment additions                            (1,906)          (1,750)
    Additions to intangibles and other assets                              --              (26)
                                                                     --------         --------
         Net cash provided by (used in) investing activities           (1,906)             762
                                                                     --------         --------
Cash flows provided by (used in) financing activities:
    Borrowings under long-term debt                                    24,500            4,250
    Principal payments under long-term debt                              (104)            (111)
    Borrowings under short-term lines of credit                         1,500               --
    Repayments of short-term lines of credit                          (17,250)          (3,500)
    Acquisition of treasury stock                                          --           (2,480)
    Dividends paid                                                         --             (524)
                                                                     --------         --------
          Net cash provided by (used in) financing activities           8,646           (2,365)
                                                                     --------         --------

Effect of exchange rate changes on cash                                   (27)              (4)
                                                                     --------         --------

Net decrease  in cash and cash equivalents                             (1,200)          (2,400)

Cash and cash equivalents at beginning of year                          3,585            3,731
                                                                     --------         --------

Cash and cash equivalents at end of period                           $  2,385         $  1,331
                                                                     ========         ========
</TABLE>

         The accompanying notes are an integral part of the consolidated
                             financial statements.

                                     - 5 -
<PAGE>

                     DEL LABORATORIES, INC. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS


1.    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

      The accompanying unaudited consolidated financial statements of Del
      Laboratories, Inc. and subsidiaries (the Company) have been prepared in
      accordance with generally accepted accounting principles for interim
      financial information and with the instructions to Form 10-Q. Accordingly,
      they do not include all of the information and footnotes required by
      generally accepted accounting principles for complete financial
      statements. Interim results are not necessarily indicative of results for
      a full year.

      A summary of the Company's significant accounting policies is presented in
      its 1999 Annual Report to Shareholders. Users of financial information
      produced for interim periods are encouraged to refer to the footnotes
      contained in the Annual Report to Shareholders when reviewing interim
      financial results.

      In the opinion of management, the accompanying interim financial
      statements contain all material adjustments, consisting only of normal
      recurring adjustments, necessary to present fairly the consolidated
      financial position, results of operations and cash flows of the Company
      for interim periods.

2.    INVENTORY

      Classification of inventories (in thousands):

                                   March 31             December 31
                                     2000                  1999
                                    -------               -------

      Raw Materials                 $34,428               $27,936
      Work In Process                 4,721                 6,226
      Finished Goods                 23,841                24,993
                                    -------               -------
                                    $62,990               $59,155
                                    =======               =======

3.    EARNINGS PER SHARE

      Basic earnings per share is computed by dividing income available to
      common shareholders (which for the Company equals its recorded net income)
      by the weighted-average number of common shares outstanding during the
      period. Diluted earnings per share reflects the potential dilution that
      could occur if securities or other contracts to issue common stock, such
      as stock options, were exercised, converted into common stock or otherwise
      resulted in the issuance of common stock.

      On November 15, 1999, the Company's Board of Directors approved a 2% stock
      dividend. As a result, 147,581 shares of treasury stock were issued on
      December 28, 1999 to shareholders of record on November 30, 1999.
      Accordingly, the weighted average common shares outstanding in the
      consolidated statement of earnings for the quarter ended March 31, 1999,
      have been restated to reflect the dividend.


                                       -6-
<PAGE>


      3.   EARNINGS PER SHARE (CONTINUED)

           A reconciliation between the numerators and denominators of the basic
           and diluted income per common share is as follows:

                                                  (Amounts in thousands,
                                                  except per share data)

                                                    Three Months Ended
                                                         March 31
                                                   --------------------
                                                    2000          1999
                                                   ------        ------

      Net earnings (numerator)                     $  501        $  366
                                                   ------        ------
      Weighted-average common shares
         (denominator for basic earnings
         per share)                                 7,545         7,621

      Effect of dilutive securities:
         Employee stock options                        76           448

      Weighted-average common and potential
         common shares outstanding
         (denominator for diluted earnings
         per share)                                 7,621         8,069
                                                   ------        ------

      Basic earnings per share                     $ 0.07        $ 0.05
                                                   ------        ------

      Diluted earnings per share                   $ 0.07        $ 0.05
                                                   ======        ======

      Employee stock options for 1,271,000 and 242,000 shares for the periods
      ended March 31, 2000 and 1999, respectively, were not included in the net
      earnings per share because their effect would have been anti-dilutive.

4.    SUPPLEMENTAL CASH FLOW INFORMATION

      The Company purchased a 68,000 square foot manufacturing, warehousing and
      office facility in Barrie, Ontario for $1,828,000. The purchase was
      financed with a combination of a mortgage bridge loan and a five-year
      mortgage.

5.    COMPREHENSIVE INCOME

      The components of comprehensive income for the three months ended March
      31, 2000 and 1999 are as follows:

                                             Three Months Ended
                                                  March 31
                                             ------------------
                                              2000         1999
                                             -----        -----

      Net earnings                           $ 501        $ 366

      Other comprehensive:
         Foreign currency translation           10          (28)
                                             -----        -----

      Total comprehensive income             $ 511        $ 338
                                             =====        =====


                                       -7-
<PAGE>

6.    SEGMENT INFORMATION

      The Company operates in two segments, Cosmetic and Pharmaceutical, that
      have been organized by the products and services they offer. The Cosmetic
      segment's principal products are nail care, nail color, color cosmetics,
      beauty implements, bleaches and depilatories, personal care products and
      other related cosmetic items. The Pharmaceutical segment's principal
      products are proprietary oral analgesics, acne treatment products and
      first aid products. The accounting policies of the segments are the same
      as those described in the summary of significant accounting policies. The
      Company evaluates the performance of its operating segments based on
      operating income. Certain assets, including property, plant and equipment
      and deferred tax assets, are not allocated to the identifiable segments;
      depreciation of unallocated assets are charged to the Cosmetic segment.

                                                 For the period ended
                                                       March 31,
                                                    (in thousands)
                                            -------------------------------
                                              2000                   1999
                                            --------               --------
Net sales
          Cosmetic                          $ 52,325               $ 46,701
          Pharmaceutical                      15,057                 15,055
                                            --------               --------
          Consolidated                      $ 67,382               $ 61,756
                                            ========               ========
Operating income (loss)
          Cosmetic                          $    743               $ (2,200)
          Pharmaceutical                       2,198                  2,287
                                            --------               --------
          Consolidated                      $  2,941               $     87
                                            --------               --------

Gain on asset sale                                --               $  1,734
                                            --------               --------
Interest expense, net                       $  2,078               $  1,211
                                            --------               --------
Earnings before taxes                       $    863               $    610
                                            ========               ========
Depreciation and amortization
          Cosmetic                          $  1,654               $  1,645
          Pharmaceutical                         113                    113
                                            --------               --------
          Consolidated                      $  1,767               $  1,758
                                            ========               ========

7.    SUBSEQUENT EVENTS

      On April 3, 2000, the Company sold a 39,000 square foot manufacturing,
      warehousing and office facility in Barrie, Ontario that was included in
      property, plant and equipment at March 31, 2000, with a net book value of
      approximately $451,000, for proceeds of approximately $862,000.
      Approximately $640,000 of the proceeds were used to satisfy a mortgage
      bridge loan on its new facility in Barrie, Ontario purchased on February
      22, 2000.

      On April 26, 2000, the Company refinanced its purchase money promissory
      note of $3,822,000 for its property in North Carolina with a five-year
      $4,523,000 mortgage on the land and buildings. The mortgage includes terms
      which provide for the maintenance of certain financial ratios. As a result
      of this refinancing the note has been classified as long-term debt in the
      accompanying consolidated balance sheet as of March 31, 2000.


                                       -8-
<PAGE>

Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations

(1)   RESULTS OF OPERATIONS

      FIRST QUARTER ENDED MARCH 31, 2000 VERSUS MARCH 31, 1999

      NET SALES

      Net sales for the first quarter of 2000 were $67.4 million, an increase of
      9.1% compared to $61.8 million in the first quarter of 1999. Cosmetics net
      sales for the first quarter of 2000 were $52.3 million, an increase of
      12.0% compared to $46.7 million in 1999. The increase is due principally
      to lower product returns.

      Pharmaceuticals net sales were $15.1 million for the first quarter of 2000
      and 1999.

      COST OF SALES

      Cost of sales for the first quarter of 2000 were $29.0 million, or 43.0%
      of net sales, as compared to $27.8 million, or 45.0% of net sales in 1999.
      The decrease in cost of sales as a percentage of net sales is due
      principally to lower product returns in the cosmetics division.

      SELLING AND ADMINISTRATIVE EXPENSES

      Selling and administrative expenses for the first quarter of 2000 were
      $35.5 million, or 52.7% of net sales, compared to $33.9 million, or 54.9%
      of net sales in 1999. The decrease as a percentage of net sales is due
      primarily to the favorable impact on net sales of lower product returns.

      NET INTEREST EXPENSE

      Interest expense, net of interest income, for the first quarter of 2000
      was $2.1 million, compared to $1.2 million in 1999. The increase is due to
      higher average borrowings for working capital requirements in the first
      quarter of 2000, in addition to increased borrowing rates, as compared to
      1999.

      INCOME TAXES

      Income taxes are based on the Company's expected annual effective tax rate
      of 42% in 2000 compared to 40% in 1999.

      NET EARNINGS

      Net earnings for the first quarter of 2000 were $0.5 million, compared to
      $0.4 million in 1999. The first quarter of 1999 included an after tax-gain
      of $1.0 million on the sale of a facility.


                                      -9-
<PAGE>

(2)   LIQUIDITY AND CAPITAL RESOURCES

      At March 31, 2000 the Company had cash and cash equivalents of $2.4
      million compared to $1.3 million at March 31, 1999.

      Net cash used in operating activities was $7.9 million for the three
      months ended March 31, 2000, primarily due to an increase in accounts
      receivable of $10.4 million, an increase in inventories of $3.9 million,
      partially offset by increases of $2.7 million in accounts payable and $2.2
      million in accrued liabilities.

      Cash used for property, plant and equipment additions was $1.9 million for
      the three months ended March 31, 2000 compared to $1.8 million in 1999.

      Net cash provided by financing activities for the three months ended March
      31, 2000 was $8.6 million due to proceeds received under the Company's
      revolving credit agreement and short-term borrowings under a line of
      credit with a bank, partially offset by repayments of short-term
      borrowings.

      On February 22, 2000, the Company purchased a 68,000 square foot
      manufacturing, warehousing and office facility in Barrie, Ontario for
      $1,828,000. The purchase was financed with a combination of a mortgage
      bridge loan and a five-year mortgage. The 39,000 square foot
      manufacturing, warehousing and office facility in Barrie, Ontario that was
      included in property, plant and equipment at March 31, 2000, with a net
      book value of approximately $451,000, was sold on April 3, 2000 for
      proceeds of approximately $862,000 of which approximately $640,000 were
      used to satisfy the mortgage bridge loan.

      Under the Company's purchase money promissory note for its property in
      North Carolina, the final payment of $3,850,000 was due on May 15, 2000.
      On April 26, 2000, the Company refinanced this note with a five-year
      mortgage on the land and buildings. The mortgage includes terms which
      provide for the maintenance of certain financial ratios.

      The Company believes that cash from future operations, cash on hand and
      amounts available from the credit facility, will be sufficient to satisfy
      its liquidity needs for the foreseeable future.


                                      -10-
<PAGE>

      NEW ACCOUNTING PRONOUNCEMENTS

      The Financial Accounting Standards Board issued Statement of Financial
      Accounting Standard No. 133, "Accounting for Derivative Instruments and
      Hedging Activities" (SFAS No. 133) as amended by SFAS 137, which is
      effective for quarters of fiscal years beginning after June 15, 2000. SFAS
      No. 133 provides guidance for accounting for all derivative instruments,
      including certain derivative instruments embedded in other contracts, and
      for hedging activities. The Company does not believe that the
      implementation of SFAS No. 133 will have a significant impact on its
      financial position or results of operations.

      FORWARD - LOOKING STATEMENTS

      Management's Discussion and Analysis of the Results of Operations and
      Financial Condition and other sections of this Form 10-Q include
      "forward-looking statements" within the meaning of Section 27A of the
      Securities Act of 1933 and Section 21E of the Securities and Exchange Act
      of 1934 (the "Exchange Act"). All statements other than statements of
      historical information provided herein are forward-looking statements and
      may contain information about financial results, economic conditions,
      trends and known uncertainties. The forward-looking statements contained
      herein are subject to certain risks and uncertainties that could cause
      actual results to differ materially from those reflected in the
      forward-looking statements. Factors that might cause such a difference
      include, but are not limited to, delays in introducing new products or
      failure of consumers to accept new products, actions by competitors which
      may result in mergers, technology improvement or new product
      introductions, the dependence on certain national chain drug stores and
      mass merchandiser relationships due to the concentration of sales
      generated by such chains, changes in fashion oriented color cosmetics
      trends, and trends in the general economy.

      Readers are cautioned not to place undue reliance on these forward-looking
      statements, which reflect management's analysis, judgment, belief or
      expectation only as of the date hereof. The Company undertakes no
      obligation to publicly revise these forward-looking statements to reflect
      events or circumstances that arise after the date hereof. In addition to
      the disclosure contained herein, readers should carefully review any
      disclosure of risks and uncertainties contained in other documents the
      Company files or has filed from time to time with the Securities and
      Exchange Commission pursuant to the Exchange Act.



                                      -11-
<PAGE>

PART II - OTHER INFORMATION



Item 6. EXHIBITS AND REPORTS ON FORM 8-K

      (a)   Exhibit 27.1 Financial Data Schedule


      (b)   Reports on Form 8-K

            None














                                      -12-
<PAGE>

                                   SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.




                                      DEL LABORATORIES, INC.
                                      ----------------------
                                      (Registrant)




DATE: MAY 5, 2000                     /s/ Dan K. Wassong
                                      ----------------------------
                                      Dan K. Wassong
                                      Chairman, President and
                                      Chief Executive Officer




DATE: MAY 5, 2000                     /s/ Enzo J. Vialardi
                                      ----------------------------
                                      Enzo J. Vialardi
                                      Executive Vice President and
                                      Chief Financial Officer






                                      -13-